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LETTER TO THE EDITOR
Monitoring for post-transplant hepatocellular carcinoma recurrence
Sir,
In identifying the risks for recurrent hepatocellular carcinoma
(HCC) after liver transplantation, Nissen and colleagues propose
that this group of patients can be monitored with less rigidity.1 We
believe that this conclusion is not well supported. Roayaie et al.2
and Sotiropoulos et al.3 have reported tumour recurrence rates in
the range of 8–18%. Amongst the last 28 transplants performed at
this centre for HCC, we encountered five instances (17.9%) of
rapid recurrence (within 15 months). One patient was initially
considered to be outside the Milan criteria, but was downstaged.
Two patients were outside Milan criteria following examination of
the explanted liver. Four patients had a moderately elevated
alphafetoprotein (AFP) level (54.0–114.5 U) and one patient had
a poorly differentiated tumour.
In the HCC Clinical Practice Guidelines,4 the authors propose
that patients should be followed monthly for 6 months, then once
every 3 months up to 1 year, twice per year up to 2 years and once
every year thereafter for life. We think that accepting non-rigid
follow-up for patients whose disease characteristics fall within the
Milan criteria is not justified. Other factors, such as vascular inva-
sion, tumour differentiation5 and AFP slope,6 play various roles.
The early detection of recurrence and the surgical management of
affected patients is related to increased survival.2 We support the
view of Kneteman et al.,6 who recommend that follow-up should
be defined according to the risk of each patient, based on AFP
levels at transplant, status regarding Milan criteria at listing and
explant, and pathology features such as microvascular invasion,
tumour grade and microsatellitosis.
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